MiR-183 exerts tumor-promoting effects in ovarian cancer by regulating one of the transcription factor proteins, Mothers against decapentaplegic homolog 4 (Smad 4), via the TGF-β/Smad4 pathway. Here, SMAD4 is linked to neoplasm.